Literature DB >> 12893832

Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand.

Jeong-Ki Min1, Young-Myeong Kim, Young-Mi Kim, Eok-Cheon Kim, Yong Song Gho, Il-Jun Kang, Soo-Young Lee, Young-Yun Kong, Young-Guen Kwon.   

Abstract

Vascular endothelial growth factor (VEGF) is known as a key regulator of angiogenesis during endochondral bone formation. Recently, we demonstrated that TNF-related activation-induced cytokine (TRANCE or RANKL), which is essential for bone remodeling, also had an angiogenic activity. Here we report that VEGF up-regulates expression of receptor activator of NF-kappa B (RANK) and increases angiogenic responses of endothelial cells to TRANCE. Treatment of human umbilical vein endothelial cells (HUVECs) with VEGF increased both RANK mRNA and surface protein expression. Although placenta growth factor specific to VEGF receptor-1 had no significant effect on RANK expression, inhibition of downstream signaling molecules of the VEGF receptor-2 (Flk-1/KDR) such as Src, phospholipase C, protein kinase C, and phosphatidylinositol 3'-kinase suppressed VEGF-stimulated RANK expression in HUVECs. Moreover, the MEK inhibitor PD98059 or expression of dominant negative MEK1 inhibited induction of RANK by VEGF but not the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA-AM). VEGF potentiated TRANCE-induced ERK activation and tube formation via RANK up-regulation in HUVECs. Together, these results show that VEGF enhances RANK expression in endothelial cells through Flk-1/KDR-protein kinase C-ERK signaling pathway, suggesting that VEGF plays an important role in modulating the angiogenic action of TRANCE under physiological or pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893832     DOI: 10.1074/jbc.M300539200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  In vitro models for the evaluation of angiogenic potential in bone engineering.

Authors:  Elisabetta Cenni; Francesca Perut; Nicola Baldini
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

Review 2.  Mechanisms of tooth eruption and orthodontic tooth movement.

Authors:  G E Wise; G J King
Journal:  J Dent Res       Date:  2008-05       Impact factor: 6.116

3.  Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1.

Authors:  I K Lukić; D Grcević; N Kovacić; V Katavić; S Ivcević; I Kalajzić; A Marusić
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.

Authors:  Xin Mao; Xiaoyun Pan; Song Zhao; Xiaochun Peng; Tao Cheng; Xianlong Zhang
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

5.  An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Authors:  Paola Secchiero; Federica Corallini; Assunta Pandolfi; Agostino Consoli; Riccardo Candido; Bruno Fabris; Claudio Celeghini; Silvano Capitani; Giorgio Zauli
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

6.  Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.

Authors:  Gabriella Misso; Manuela Porru; Antonella Stoppacciaro; Maria Castellano; Federica De Cicco; Carlo Leonetti; Daniele Santini; Michele Caraglia
Journal:  Cancer Biol Ther       Date:  2012-09-18       Impact factor: 4.742

Review 7.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

8.  RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas.

Authors:  Anna von dem Knesebeck; Jörg Felsberg; Anke Waha; Wolfgang Hartmann; Björn Scheffler; Martin Glas; Jennifer Hammes; Thomas Mikeska; Pearlly S Yan; Elmar Endl; Matthias Simon; Guido Reifenberger; Torsten Pietsch; Andreas Waha
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

9.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis.

Authors:  David C Markel; Renwen Zhang; Tong Shi; Monica Hawkins; Weiping Ren
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.